Korean J Hepatol.
2008 Dec;14(4):493-502. 10.3350/kjhep.2008.14.4.493.
Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: A comparative study
- Affiliations
-
- 1Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea. midoctor@cnuh.co.kr
- 2Department of Internal Medicine, College of Medicine, Konyang University, Daejeon, Korea.
- 3Department of Internal Medicine, Eulji University College of Medicine, Daejeon, Korea.
- 4Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Daejeon, Korea.
- 5Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Korea.
- 6Department of Internal Medicine, College of Medicine, Dankook University, Cheonan, Korea.
- 7Department of Internal Medicine, College of Medicine, Soonchunhyang University, Cheonan, Korea.
- KMID: 1073301
- DOI: http://doi.org/10.3350/kjhep.2008.14.4.493
Abstract
- BACKGROUNDS/AIMS: Peginterferon alpha-2a or -2b is the standard treatment regimen in chronic hepatitis C. However, there have been few comparative studies of the efficacies of these two types of peginterferon. We evaluated their efficacies in combination with ribavirin as a initial treatment for chronic hepatitis C. METHODS: Ninety-seven patients were treated with peginterferon alpha-2a (180 microgram/week, n=48) or peginterferon alpha-2b (1.5 microgram/kg/week, n=49) plus ribavirin (800 mg/day for 24 weeks in genotype non-1 or 1,000-1,200 mg/day for 48 weeks in genotype 1). Virologic responses including the early virologic response (EVR), end-of-treatment response (ETR), sustained virologic response (SVR), and adverse effects were analyzed retrospectively. RESULTS: The virologic response rates did not differ significantly between peginterferon alpha-2a and -2b: 89.6% and 89.7% for EVR, 79.2% and 79.5% for ETR, 72.9% and 73.5% for SVR, respectively. Analysis of the virologic responses according to genotype also revealed no significant differences in SVR between peginterferon alpha-2a and -2b (59.3% vs. 59.7% for genotype 1 and 90.5% vs. 83.3% for genotype non-1, respectively), or in adverse effects including flu-like symptom, rash, itching, neutropenia, and thrombocytopenia. CONCLUSIONS: We found no significant differences in therapeutic efficacies and adverse effects between the alpha-2a and -2b types of peginterferon as the initial treatment regimen in naive chronic hepatitis C patients.
Keyword
MeSH Terms
-
Adult
Antiviral Agents/*administration & dosage
Combined Modality Therapy
Genotype
Hepacivirus/drug effects/genetics
Hepatitis C, Chronic/diagnosis/*drug therapy
Humans
Interferon Alfa-2a/*administration & dosage
Interferon Alfa-2b/*administration & dosage
Korea
Middle Aged
Polyethylene Glycols/*administration & dosage
Retrospective Studies
Ribavirin/*administration & dosage
Risk Factors
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment of chronic hepatitis C: Efficacy of initial treatment of peginterferon alpha-2a versus peginterferon alpha-2b plus ribavirin in naive chronic hepatitis C patients
- Peginterferon-alpha and Ribavirin Combination Therapy in Chronic Hepatitis C
- The Combination Therapy with Peg-interferon Alfa and Ribavirin for Chronic Hepatitis C in Korea as an Initial Treatment
- Permanent sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment
- Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response
